NEW

Perlin Named President of The Joint Commission

The Board of Commissioners of The Joint Commission have announced the appointment of Dr. Jonathan B. Perlin to lead The Joint Commission as its next President and CEO. The appointment is effective March 1, 2022. Widely known for his leadership in healthcare quality...

Session Addresses OR Metrics

In this 60-minute webinar, Brooks DuBose from LeanTaaS’ iQueue for Operating Rooms implementation team explained where the opportunities lie and how to drill down to come up with actionable steps and strategies for meaningful performance improvement. Turnovers and delays are good indicators of efficiency.

Healthmark Offers New Instrument Protectors

Healthmark Industries recently introduced the Instrument Protectors to its ProSys Instrument Care product line. The single-use Instrument Protectors provide protection for sharp and fragile items to the point of use. Manufactured from SBS paperboard, the Instrument...

New Data on OviTex in Hernia Repair Applications

TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, has announced details of the clinical research presented last...

New Biomaterials Can Be ‘Fine-tuned’ for Medical Applications

New Biomaterials Can Be ‘Fine-tuned’ for Medical Applications

Researchers in the UK and the United States have succeeded in “fine tuning” a new thermoplastic biomaterial to enable the rate at which it degrades in the body and its mechanical properties to be controlled independently.

The material, a type of polyester, has been designed for use in soft tissue repair or flexible bioelectronics by a team at the University of Birmingham in the UK and Duke University in the U.S.

Materials that successfully replicate the necessary elasticity and strength of biological tissues, but which also biodegrade over an appropriate timescale are extremely difficult to engineer. This is because the chemistry used to produce a material’s mechanical properties will also typically govern the rate at which it degrades.

In a new advance, the team has now shown how the addition of succinic acid – a product found naturally within the body – can be used to control the degradation rate.

In a new study, published in Nature Communications, researchers showed how the polyester biomaterial degrades gradually over a period of four months, with healthy tissues growing into and eventually replacing the implant. Tests in rats were also carried out to confirm the material’s biocompatibility and safety.

By varying the amounts of succinic acid, the team could control the rate at which water penetrates the material and hence the degradation speed. Usually, the structural changes that increase degradation speed would cause a loss of strength, but this material has been designed with specific stereochemistry that mimics natural rubber and allow its mechanical properties to be finely controlled. This means any loss of strength can be compensated for by making suitable stereochemical adjustments. This is a significant advance that has so far not been achieved in any other degradable biomaterial.

Co-author of the study Professor Andrew Dove explains, “Biological tissues are complex with varying elastic properties. Efforts to produce synthetic replacements that have the right physical characteristics and that can also degrade in the body have been ongoing for decades. Part of the challenge is that a ‘one-size-fits-all’ approach doesn’t work. Our research opens up the possibility of engineering biological implants with properties that can be fine-tuned for each specific application.”

Professor Matthew Becker, who holds dual appointments in chemistry and mechanical engineering and materials science at Duke, notes that the biomaterials and regenerative medicine communities have been severely limited to a few materials which lack the diversity of properties reported in this study.

“The materials we have developed offer a real advance in the ongoing search for new biomaterials,” Becker said. “The tunable nature of the material makes it suitable for a range of different applications, from replacement bone to vascular stents to wearable electronics. Additional work to prove the biocompatibility of the material and its use in more advanced demonstration is ongoing.”

The research was funded by the National Science Foundation, the John S. and James L. Knight Foundation, the European Research Foundation and the National Health and Medical Research Council of Australia.

The technology is the subject of international patent applications filed by the University of Warwick and Akron University.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X